Bivalent IL-2 Fusion Toxin Treg Depletion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments face challenges in effectively depleting regulatory T cells (Tregs) to enhance anti-tumor immune responses, as existing methods like Ontak have limitations in Treg depletion and cause unwanted side effects.
Innovation Solution
Development of bivalent IL-2 fusion toxins, comprising a cytotoxic protein linked with two IL-2 sequences, which are expressed in methylotropic yeast like Pichia Pastoris, to specifically target and deplete CD25+ cells, thereby relieving immune suppression and promoting anti-tumor responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monovalent IL-2 fusion toxin is used, then Treg depletion can be achieved, but the potency is insufficient and side effects occur
Solution Approach 1:
The patent divides the single IL-2 binding site into two separate IL-2 sequences within the fusion toxin structure. This segmentation allows the toxin to engage multiple CD25 receptors simultaneously, enhancing binding affinity and potency while maintaining selectivity for Treg cells, thereby reducing off-target side effects
Solution Approach 2:
The fusion toxin combines a cytotoxic protein (diphtheria toxin or Pseudomonas exotoxin) with two IL-2 sequences to create a composite molecular structure. This composite design integrates the targeting capability of IL-2 with the cytotoxic function, achieving potent and selective Treg depletion with improved therapeutic index
2Measurement precision
If cytotoxic protein is linked with IL-2 sequences, then CD25+ cell targeting is achieved, but protein synthesis inhibition and cell proliferation inhibition potency need enhancement
Solution Approach 1:
The patent merges the targeting function of IL-2 sequences with the cytotoxic function of diphtheria toxin or Pseudomonas exotoxin into a single fusion protein. The two IL-2 sequences are linked to the cytotoxic domain, creating a unified molecule that simultaneously targets CD25+ cells and delivers cytotoxic effect, thereby enhancing both specificity and potency
Solution Approach 2:
The patent transitions from monovalent to bivalent IL-2 fusion toxin architecture, adding a second binding dimension. This bivalent structure enables simultaneous engagement of multiple CD25 receptors on target cells, increasing binding valency and thereby enhancing potency through multivalent interaction
Data Source
AI summary
IL-2 fusion toxins, e.g., bivalent-IL2 fusion toxins, and methods of use thereof.